Approvals/TGA/PAVTIDE MDI 250/25 fluticasone propionate 250 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)

Approved

STANDARD

PAVTIDE MDI 250/25 fluticasone propionate 250 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)

GlaxoSmithKline Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 30, 2025
Approval ID: b19331d9cb9ca917
Company: GlaxoSmithKline Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: b19331d9cb9ca917
Product Name: PAVTIDE MDI 250/25 fluticasone propionate 250 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
Artg Id: 208671
Artg Name: PAVTIDE MDI 250/25 fluticasone propionate 250 mcg/salmeterol (as xinafoate) 25 mcg inhalation pressurised aerosol can metered dose (with counter)
Sponsor: GlaxoSmithKline Australia Pty Ltd
Company Detail Path: /organization/glaxosmithkline-australia-pty-ltd
Artg Date: 2014-05-07
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2019-CMI-01544-1
Product Information: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2014-PI-01827-1

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

b19331d9cb9ca917

Type

Standard

Back to TGA Approvals